lymphokine production
Recently Published Documents


TOTAL DOCUMENTS

195
(FIVE YEARS 0)

H-INDEX

35
(FIVE YEARS 0)

Author(s):  
H. Arvilommi ◽  
Liisa RäSäNen ◽  
Aino Laatikainen ◽  
Eliisa KarhumäKi

2004 ◽  
Vol 128 (3) ◽  
pp. 259-265 ◽  
Author(s):  
Javier Schlatter ◽  
Felipe Ortuño ◽  
Salvador Cervera-Enguix

Infection ◽  
2000 ◽  
Vol 28 (1) ◽  
pp. 42-45 ◽  
Author(s):  
M. Kori ◽  
V. Barak ◽  
E. Leibovitz ◽  
Y. Altman ◽  
A. Eliraz ◽  
...  

Virology ◽  
1999 ◽  
Vol 261 (2) ◽  
pp. 165-172 ◽  
Author(s):  
Maria-Christina Jung ◽  
Bertram Hartmann ◽  
Jörn-Tilman Gerlach ◽  
Helmut Diepolder ◽  
Rudolf Gruber ◽  
...  

1999 ◽  
Vol 6 (4-5) ◽  
pp. 301-309 ◽  
Author(s):  
Katherine Tepperman ◽  
Pamela W. Roy ◽  
Brian F. Moloney ◽  
R. C. Elder

Having identified dicyanogold(I) as a common metabolite of gold-based antiarthritis drugs, we are investigating the effects of the compound on the production of lymphokines. Handel, et al. 1 suggested that the transcription factor AP-1, critical to the production of a number of cytokines, might be the target for gold compounds because of a critical cysteine within its DNA binding region. Using Jurkat cells, an established cell line as a model for CD4+ lymphocytes, we have shown that dicyanogold inhibits the binding of AP-1 to DNA and inhibits the synthesis of IL-2 mRNA and protein. In a macrophage line, THP-1, which synthesizes IL-1β in response to mitogen, we have shown that dicyanogold inhibits the binding of a second transcription factor, CREB to DNA. Incubation of THP-1 cells with dicyanogold inhibits the production of IL-1β mRNA. These results suggest that the mechanism of action of gold drugs may be through their interaction with transcription factors necessary for the immune activation seen in Rheumatoid Arthritis.


Sign in / Sign up

Export Citation Format

Share Document